NG-641
UNII L93WSG9AAU
Substance Identification & Data
This profile provides standardized clinical and technical data for Ng-641, uniquely identified by the FDA Unique Ingredient Identifier (UNII) L93WSG9AAU.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
L93WSG9AAU
N/A
N/A
Detailed Substance Profile
Preferred Name
NG-641
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
Substance Type
structurallyDiverse
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Ng-641. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
Common Names & Synonyms
NG 641 [WHO-DD]
NG-641 (AN ONCOLYTIC ADENOVIRAL VECTOR ENCODES FOUR SEPARATE GENES: A FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETING BISPECIFIC T-CELL ACTIVATOR (FAP-TAC) TO ACTIVATE T-CELLS AND DECREASE THE TUMOR ASSOCIATED FIBROBLASTS IN TUMOR STROMA, CHEMOKINES CXCL9 AND CXCL10 TO RECRUIT T-CELLS, INTERFERON ALPHA TO DRIVE DENDRITIC CELL PRIMING AND FURTHER ACTIVATE T-CELLS)
ONCOLYTIC ADENOVIRAL VECTOR WHICH EXPRESSES A FAP-TAC ANTIBODY TOGETHER WITH AN IMMUNE ENHANCER MODULE (CXCL9/CXCL10/IFN.ALPHA.)
Technical Codes
NG641
NG-641
